Reset filter
Palavras-chave
On-Study Form ×
Mostrar mais Palavras-chave
Índice
  1. 1. Estudo clínico
  2. 2. Documentação de rotina
  3. 3. Estudos de registo/coortes
  4. 4. Garantia da qualidade
  5. 5. Padrão de dados
  6. 6. Questionário do paciente
  7. 7. Especialidade médica
    1. 7.1. Anestesia
    1. 7.2. Dermatologia
    1. 7.3. Otorrinolaringologia
    1. 7.4. Geriatria
    1. 7.5. Ginecologia/obstetrícia
    1. 7.6. Medicina interna
      1. Hematologia
      1. Infecciologia
      1. Cardiologia/angiologia
      1. Pneumologia
      1. Gastroenterologia
      1. Nefrologia
      1. Endocrinologia/metabolismo
      1. Reumatologia
    1. 7.7. Neurologia
    1. 7.8. Oftalmologia
    1. 7.9. Medicina paliativa
    1. 7.10. Patologia/medicina Legal
    1. 7.11. Pediatria
    1. 7.12. Psiquiatria/psicossomática
    1. 7.13. Radiologia
    1. 7.14. Cirurgia
      1. Cirurgia geral/abdominal
      1. Neurocirurgia
      1. Cirurgia plástica
      1. Cirurgia cardíaca/torácica
      1. Cirurgia de trauma/ortopedia
      1. Cirurgia vascular
    1. 7.15. Urologia
    1. 7.16. Odontologia/cirurgia bucomaxilofacial
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

44 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Safety and Efficacy of Argatroban in Pediatric Patients, NCT00039858 - Dosing Information - Circuit Prime and Bolus

- 03/09/2020 - 1 Formulário, 3 Grupos de itens, 15 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Dosing Information - Circuit Prime, Dosing Information - Bolus
Study ID: 105043/013 Clinical Study ID: 105043/013 Study Title: An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin (Protocol SKF105043/013) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00039858 Sponsor: GlaxoSmithKline Collaborators: Encysive Pharmaceuticals Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Argatroban Trade Name: N/A Study Indication: Thrombosis This Study evaluates the safety and the efficacy of i.v. Argatroban treatment in paediatric patients which require anticoagulants but aren't suitable for Heparin treatment. The study consists of screening visit (pre-treatment examination), treatment period of maximum 14 days after reaching therapeutical dose, post-treatment visit (once the treatment is stopped or after 14 days) and a follow-up visit which follows 30 days (+/- 14 days) after clinical resolution of underlying condition or after the end of the 14-day study period. Treatment can be continued after the 14-day study period if needed but such treatment isn't part of this Study. See https://clinicaltrials.gov/ct2/show/NCT00039858 This Form has to be filled in during the Treatment period after Circuit Prime is administered and whenever a Bolus of Argatroban is administered. Continuous infusions are recorded in a separate form.

Meningococcal Infections Vaccination in children NCT00196976 - Workbook 2 Visit 2 Part 1

- 03/11/2017 - 1 Formulário, 3 Grupos de itens, 8 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Documentation, Study Continuation, Laboratory Tests
Study ID: 103533 Clinical Study ID: 103533 Study Title: Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 months & 3-5 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00196976 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed clinical study under GSK sponsorship. The product that is studied in this clinical study, together with the rights to the data and results generated, has been transferred by GSK to Pfizer. GSK’s Clinical Study Register is no longer maintained for this study. To request access to clinical study data from Pfizer, go here: http://www.pfizer.com/research/clinical_trials/trial_data_and_results Generic Name: Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine Trade Name: Nimenrix Study Indication: Infections, Meningococcal

Meningococcal Infections Vaccination in children NCT00196976 - Workbook 1 Visit 2 Part 1

- 03/11/2017 - 1 Formulário, 3 Grupos de itens, 8 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Documentation, Study Continuation, Laboratory Tests
Study ID: 103533 Clinical Study ID: 103533 Study Title: Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 months & 3-5 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00196976 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed clinical study under GSK sponsorship. The product that is studied in this clinical study, together with the rights to the data and results generated, has been transferred by GSK to Pfizer. GSK’s Clinical Study Register is no longer maintained for this study. To request access to clinical study data from Pfizer, go here: http://www.pfizer.com/research/clinical_trials/trial_data_and_results Generic Name: Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine Trade Name: Nimenrix Study Indication: Infections, Meningococcal

Meningococcal Infections Vaccination in children NCT00196976 - Workbook 1 Visit 3

- 03/11/2017 - 1 Formulário, 2 Grupos de itens, 7 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Documentation, Study Continuation
Study ID: 103533 Clinical Study ID: 103533 Study Title: Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 months & 3-5 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00196976 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed clinical study under GSK sponsorship. The product that is studied in this clinical study, together with the rights to the data and results generated, has been transferred by GSK to Pfizer. GSK’s Clinical Study Register is no longer maintained for this study. To request access to clinical study data from Pfizer, go here: http://www.pfizer.com/research/clinical_trials/trial_data_and_results Generic Name: Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine Trade Name: Nimenrix Study Indication: Infections, Meningococcal

Meningococcal Infections Vaccination in children NCT00196976 - Visit 2 Part 1

- 26/10/2017 - 1 Formulário, 3 Grupos de itens, 8 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Documentation, Study Continuation, Laboratory Tests
Study ID: 103533 Clinical Study ID: 103533 Study Title: Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 months & 3-5 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00196976 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed clinical study under GSK sponsorship. The product that is studied in this clinical study, together with the rights to the data and results generated, has been transferred by GSK to Pfizer. GSK’s Clinical Study Register is no longer maintained for this study. To request access to clinical study data from Pfizer, go here: http://www.pfizer.com/research/clinical_trials/trial_data_and_results Generic Name: Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine Trade Name: Nimenrix Study Indication: Infections, Meningococcal

On-Study - Pediatric Soft Tissue Sarcoma - On-Study Form Recurrent Treatment - 2292588v3.0 - Pediatric Soft Tissue Sarcoma - On-Study Form Recurrent Treatment

- 09/01/2015 - 1 Formulário, 7 Grupos de itens, 54 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, Sarcoma: Form Administration, Pediatric Soft Tissue Sarcoma: Recurrent Disease Description, Pediatric Soft Tissue Sarcoma: Prior Health History, Sarcoma: Prior Treatment, Sarcoma: Prior Treatment - Systemic Regimens, Comments
Pediatric Soft Tissue Sarcoma - On-Study Form Recurrent Treatment Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E4053EE1-90D1-2ED9-E034-0003BA3F9857

On-Study - Pediatric Soft Tissue Sarcoma - On-Study Form Newly Diagnosed Patients - 2292713v3.0 - Pediatric Soft Tissue Sarcoma - On-Study Form Newly Diagnosed Patients

- 09/01/2015 - 1 Formulário, 5 Grupos de itens, 46 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, Sarcoma: Form Administration, Pediatric Soft Tissue Sarcoma: Disease Description, Pediatric Soft Tissue Sarcoma: Prior Health History, Comments
Pediatric Soft Tissue Sarcoma - On-Study Form Newly Diagnosed Patients Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E4051BFF-CFA4-2D00-E034-0003BA3F9857

Immunogenicity of Combined Measles, Mumps, Rubella, Varicella Vaccine for healthy 2 y.o children - 104020 - Diary Card: Rash/Exanthem + Parotid/Salivary gland swelling + Febrile Convulsions - Dose 2

- 27/11/2018 - 1 Formulário, 2 Grupos de itens, 11 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Rash Episode
Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella

Immunogenicity of Combined Measles, Mumps, Rubella, Varicella Vaccine for healthy 2 y.o children - 104020 - Diary Card: Unsolicited Symptoms (All Groups) - Dose 2

- 27/11/2018 - 1 Formulário, 3 Grupos de itens, 15 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Other Symptoms (Day 0-42), Medication
Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella

Immunogenicity of Combined Measles, Mumps, Rubella, Varicella Vaccine for healthy 2 y.o children - 104020 - Diary Card: Rash/Exanthem + Parotid/Salivary gland swelling + Febrile Convulsions

- 27/11/2018 - 1 Formulário, 2 Grupos de itens, 11 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Rash Episode
Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella

Immunogenicity of Combined Measles, Mumps, Rubella, Varicella Vaccine for healthy 2 y.o children - 104020 - Diary Card: Temperature (All Groups) - Dose 2

- 27/11/2018 - 1 Formulário, 5 Grupos de itens, 14 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Temperature (day 0 - day 14), Temperature Log, Temperature (day 15 - day 42), Temperature Log
Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella

Immunogenicity of Combined Measles, Mumps, Rubella, Varicella Vaccine for healthy 2 y.o children - 104020 - Diary Card: Local Symptoms - Dose 2

- 27/11/2018 - 1 Formulário, 7 Grupos de itens, 25 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Local Symptoms (at injection site), Local Symptoms (Group MeMuRu-OKA), Local Symptoms (Group Priorix), for investigator only (Priorix vaccine), Local Symptoms (Group Varilrix), for investigator only (Varilrix vaccine)
Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial